Basit öğe kaydını göster

Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

dc.contributor.authorOzmen, Deniz
dc.contributor.authorEskazan, Ahmet Emre
dc.date.accessioned2021-03-04T18:07:38Z
dc.date.available2021-03-04T18:07:38Z
dc.date.issued2017
dc.identifier.citationEskazan A. E. , Ozmen D., "Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?", EXPERT REVIEW OF HEMATOLOGY, cilt.10, ss.583-586, 2017
dc.identifier.issn1747-4086
dc.identifier.othervv_1032021
dc.identifier.otherav_89046be2-43ff-4d80-9e5e-5ad197d8e866
dc.identifier.urihttp://hdl.handle.net/20.500.12627/92949
dc.identifier.urihttps://doi.org/10.1080/17474086.2017.1339599
dc.language.isoeng
dc.subjectHematoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectHEMATOLOJİ
dc.titleTyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
dc.typeMakale
dc.relation.journalEXPERT REVIEW OF HEMATOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume10
dc.identifier.issue7
dc.identifier.startpage583
dc.identifier.endpage586
dc.contributor.firstauthorID238322


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster